{"id": "article-31977_0", "title": "Radiation Therapy for Anal Cancer -- Continuing Education Activity", "content": "Cancers of the anal canal are rare, comprising approximately 10% of malignancies in the anorectal region, although its incidence has been increasing over the past several decades. While the traditional approach to treatment was with abdominoperineal resection (APR), this has evolved in the modern era to concurrent chemoradiation as organ-preserving treatment. This activity reviews the role of radiation therapy for anal cancer and highlights the role of the interprofessional team in the management of these patients.", "contents": "Radiation Therapy for Anal Cancer -- Continuing Education Activity. Cancers of the anal canal are rare, comprising approximately 10% of malignancies in the anorectal region, although its incidence has been increasing over the past several decades. While the traditional approach to treatment was with abdominoperineal resection (APR), this has evolved in the modern era to concurrent chemoradiation as organ-preserving treatment. This activity reviews the role of radiation therapy for anal cancer and highlights the role of the interprofessional team in the management of these patients."}
{"id": "article-31977_1", "title": "Radiation Therapy for Anal Cancer -- Continuing Education Activity", "content": "Objectives: Describe the pathophysiology of anal cancer. Review the workup of a patient suspected of having anal cancer. Outline the treatment and management options available for anal cancer. Describe interprofessional team strategies for improving care and outcomes in patients with anal cancer. Access free multiple choice questions on this topic.", "contents": "Radiation Therapy for Anal Cancer -- Continuing Education Activity. Objectives: Describe the pathophysiology of anal cancer. Review the workup of a patient suspected of having anal cancer. Outline the treatment and management options available for anal cancer. Describe interprofessional team strategies for improving care and outcomes in patients with anal cancer. Access free multiple choice questions on this topic."}
{"id": "article-31977_2", "title": "Radiation Therapy for Anal Cancer -- Introduction", "content": "Cancers of the anal canal are rare, comprising approximately 10% of malignancies in the anorectal region, although its incidence has been increasing over the past several decades. [1] [2] While the traditional approach to treatment was with abdominoperineal resection (APR), this has evolved in the modern era to concurrent chemoradiation as organ-preserving treatment.", "contents": "Radiation Therapy for Anal Cancer -- Introduction. Cancers of the anal canal are rare, comprising approximately 10% of malignancies in the anorectal region, although its incidence has been increasing over the past several decades. [1] [2] While the traditional approach to treatment was with abdominoperineal resection (APR), this has evolved in the modern era to concurrent chemoradiation as organ-preserving treatment."}
{"id": "article-31977_3", "title": "Radiation Therapy for Anal Cancer -- Introduction -- Anatomy", "content": "The anal canal runs from the anal verge (the visible junction between the internal anal canal and hair-bearing keratinized external anal skin) to the anorectal ring (the location in which the rectum enters the puborectalis sling). The anal canal is approximately 3 to 5 cm\u00a0in length. The dentate line is the anatomic boundary where mucosa changes from non-keratinized squamous epithelium to colorectal-type columnar mucosa proximally. It divides the upper and lower anal canal. The anal margin, also referred to as perianal skin, is a rim of tissue around the anus encompassed by a 5 cm radius, and it bears true squamous epithelium. Lymphatic drainage of anal cancers depends upon its location relative to the dentate line. Cancers above the dentate line drain to the presacral and internal iliac nodes. Cancers below the dentate line drain to superficial inguinal and femoral nodes.", "contents": "Radiation Therapy for Anal Cancer -- Introduction -- Anatomy. The anal canal runs from the anal verge (the visible junction between the internal anal canal and hair-bearing keratinized external anal skin) to the anorectal ring (the location in which the rectum enters the puborectalis sling). The anal canal is approximately 3 to 5 cm\u00a0in length. The dentate line is the anatomic boundary where mucosa changes from non-keratinized squamous epithelium to colorectal-type columnar mucosa proximally. It divides the upper and lower anal canal. The anal margin, also referred to as perianal skin, is a rim of tissue around the anus encompassed by a 5 cm radius, and it bears true squamous epithelium. Lymphatic drainage of anal cancers depends upon its location relative to the dentate line. Cancers above the dentate line drain to the presacral and internal iliac nodes. Cancers below the dentate line drain to superficial inguinal and femoral nodes."}
{"id": "article-31977_4", "title": "Radiation Therapy for Anal Cancer -- Etiology", "content": "High-grade anal intraepithelial neoplasia (AIN) can be a precursor to anal cancer. AIN can result from an infection with human papillomavirus (HPV), predominantly serotypes 16 and 18. HPV spreads via skin-to-skin contact and sexual intercourse. [3] Additional risk factors for anal cancer include HIV infection, multiple sexual partners, smoking, chronic immunosuppression not due to HIV, and chronic inflammatory states such as Crohn disease. [4] [5] [6] [7] HPV vaccines, when given before HPV exposure, reduce the rates of AIN and should be considered in populations at high risk for anal cancer. [8]", "contents": "Radiation Therapy for Anal Cancer -- Etiology. High-grade anal intraepithelial neoplasia (AIN) can be a precursor to anal cancer. AIN can result from an infection with human papillomavirus (HPV), predominantly serotypes 16 and 18. HPV spreads via skin-to-skin contact and sexual intercourse. [3] Additional risk factors for anal cancer include HIV infection, multiple sexual partners, smoking, chronic immunosuppression not due to HIV, and chronic inflammatory states such as Crohn disease. [4] [5] [6] [7] HPV vaccines, when given before HPV exposure, reduce the rates of AIN and should be considered in populations at high risk for anal cancer. [8]"}
{"id": "article-31977_5", "title": "Radiation Therapy for Anal Cancer -- Epidemiology", "content": "The incidence of anal canal cancer has steadily increased over the past several years, particularly among women. Currently, anal cancer constitutes 0.5% of all cancer diagnoses in the United States. In 2018, estimates were that there were 8580 cases per year in the US (5620 in women and 2960 in men) and 1160 deaths per year in the US (680 in women and 480 in men). Anal cancer is primarily a disease of older adults, with an average age in the early 60s. However, in HIV-positive patients, there is an earlier onset of disease. [9]", "contents": "Radiation Therapy for Anal Cancer -- Epidemiology. The incidence of anal canal cancer has steadily increased over the past several years, particularly among women. Currently, anal cancer constitutes 0.5% of all cancer diagnoses in the United States. In 2018, estimates were that there were 8580 cases per year in the US (5620 in women and 2960 in men) and 1160 deaths per year in the US (680 in women and 480 in men). Anal cancer is primarily a disease of older adults, with an average age in the early 60s. However, in HIV-positive patients, there is an earlier onset of disease. [9]"}
{"id": "article-31977_6", "title": "Radiation Therapy for Anal Cancer -- Pathophysiology", "content": "Anal squamous cell carcinoma has links to a complex inflammatory process commonly mediated by HPV infection (predominantly serotypes 16 and 18) [3] . HPV is a double-stranded DNA virus encoding viral proteins E6 and E7. These proteins inactivate tumor suppressor genes p53 and pRB, respectively, which prevent apoptosis and allow\u00a0the continuous\u00a0cycling of the cell, thus predisposing to malignant potential.", "contents": "Radiation Therapy for Anal Cancer -- Pathophysiology. Anal squamous cell carcinoma has links to a complex inflammatory process commonly mediated by HPV infection (predominantly serotypes 16 and 18) [3] . HPV is a double-stranded DNA virus encoding viral proteins E6 and E7. These proteins inactivate tumor suppressor genes p53 and pRB, respectively, which prevent apoptosis and allow\u00a0the continuous\u00a0cycling of the cell, thus predisposing to malignant potential."}
{"id": "article-31977_7", "title": "Radiation Therapy for Anal Cancer -- Histopathology", "content": "Anal intraepithelial neoplasia (AIN) represents the dysplastic changes that occur on a cellular level. AIN grade I is low-grade dysplasia (LGAIN), whereas AIN-II and AIN-III are grouped together as high-grade dysplasia (HGAIN). This grading system takes into account various cellular changes, such as abnormalities in the differentiation of squamous layers, mitotic activity, and nuclear membrane changes. [10]", "contents": "Radiation Therapy for Anal Cancer -- Histopathology. Anal intraepithelial neoplasia (AIN) represents the dysplastic changes that occur on a cellular level. AIN grade I is low-grade dysplasia (LGAIN), whereas AIN-II and AIN-III are grouped together as high-grade dysplasia (HGAIN). This grading system takes into account various cellular changes, such as abnormalities in the differentiation of squamous layers, mitotic activity, and nuclear membrane changes. [10]"}
{"id": "article-31977_8", "title": "Radiation Therapy for Anal Cancer -- Histopathology", "content": "Anal canal cancers are most commonly squamous cell carcinoma (75%). The remainder is often adenocarcinoma, but other rare histologic subtypes include melanomas, basaloid carcinomas, small cell carcinomas, sarcomas, and lymphomas. [3] The majority of subtypes are treated as squamous cell carcinomas without prognostic significance. Adenocarcinoma originating from the anal canal, as opposed to a low rectal cancer extending into the canal, is rare and aggressive, with a\u00a0higher rate of distant metastases.\u00a0Traditionally, management of primary adenocarcinoma of the anal canal was the same as a low rectal cancer, treated with\u00a0neoadjuvant chemoradiation followed by abdominoperineal resection (APR), resulting in a permanent colostomy. [3] As organ preservation is an active area of interest in rectal cancer, it may be reasonable for primary adenocarcinoma of the anal canal. A multicenter retrospective study from the Rare Cancer Network of 82 patients noted similar rates of locoregional relapse at 5 years in patients treated with\u00a0neoadjuvant radiation followed by surgery with definitive chemoradiation and recommend reserving APR for salvage therapy. [11]", "contents": "Radiation Therapy for Anal Cancer -- Histopathology. Anal canal cancers are most commonly squamous cell carcinoma (75%). The remainder is often adenocarcinoma, but other rare histologic subtypes include melanomas, basaloid carcinomas, small cell carcinomas, sarcomas, and lymphomas. [3] The majority of subtypes are treated as squamous cell carcinomas without prognostic significance. Adenocarcinoma originating from the anal canal, as opposed to a low rectal cancer extending into the canal, is rare and aggressive, with a\u00a0higher rate of distant metastases.\u00a0Traditionally, management of primary adenocarcinoma of the anal canal was the same as a low rectal cancer, treated with\u00a0neoadjuvant chemoradiation followed by abdominoperineal resection (APR), resulting in a permanent colostomy. [3] As organ preservation is an active area of interest in rectal cancer, it may be reasonable for primary adenocarcinoma of the anal canal. A multicenter retrospective study from the Rare Cancer Network of 82 patients noted similar rates of locoregional relapse at 5 years in patients treated with\u00a0neoadjuvant radiation followed by surgery with definitive chemoradiation and recommend reserving APR for salvage therapy. [11]"}
{"id": "article-31977_9", "title": "Radiation Therapy for Anal Cancer -- History and Physical", "content": "Clinical presentation can include bleeding (45%), pain (30%), pruritus, perianal mass, fecal\u00a0urgency, or change in the stool caliber. [12] Locally advanced tumors may have the above symptoms, as well as mucous discharge, lower extremity edema, or non-healing perianal wounds. Alternatively, early stage anal cancer can be asymptomatic and discovered incidentally upon routine examination or anoscopy, or proctoscopy. Colonoscopy alone may miss a tumor of the anal canal due to the difficulty of retroflexing the scope into the anal canal. Systemic metastasis of squamous cell anal cancer occurs in less than 10% of cases at presentation. [1] The liver and lungs are the most common sites of distant spread, and the clinical presentation of metastatic disease is dependent upon location and tumor burden.", "contents": "Radiation Therapy for Anal Cancer -- History and Physical. Clinical presentation can include bleeding (45%), pain (30%), pruritus, perianal mass, fecal\u00a0urgency, or change in the stool caliber. [12] Locally advanced tumors may have the above symptoms, as well as mucous discharge, lower extremity edema, or non-healing perianal wounds. Alternatively, early stage anal cancer can be asymptomatic and discovered incidentally upon routine examination or anoscopy, or proctoscopy. Colonoscopy alone may miss a tumor of the anal canal due to the difficulty of retroflexing the scope into the anal canal. Systemic metastasis of squamous cell anal cancer occurs in less than 10% of cases at presentation. [1] The liver and lungs are the most common sites of distant spread, and the clinical presentation of metastatic disease is dependent upon location and tumor burden."}
{"id": "article-31977_10", "title": "Radiation Therapy for Anal Cancer -- Evaluation", "content": "The initial workup of biopsy-proven squamous cell carcinoma of the anal canal should include digital rectal examination (DRE), inguinal lymph node evaluation with biopsy of suspicious nodes, chest and abdominal CT, pelvic CT/MRI, anoscopy, HIV testing (if HIV status unknown), CBC, CMP, and gynecologic exam for women, including cervical cancer screening per NCCN guidelines. PET/CT is useful in radiation treatment planning and to evaluate for distant metastatic disease. [13] PET/CT can improve inguinal nodal detection with sensitivity and specificity of 93% and 76%, respectively. [14] Sentinel lymph node biopsy may have utility in assessing the inguinal lymph nodes. [15]", "contents": "Radiation Therapy for Anal Cancer -- Evaluation. The initial workup of biopsy-proven squamous cell carcinoma of the anal canal should include digital rectal examination (DRE), inguinal lymph node evaluation with biopsy of suspicious nodes, chest and abdominal CT, pelvic CT/MRI, anoscopy, HIV testing (if HIV status unknown), CBC, CMP, and gynecologic exam for women, including cervical cancer screening per NCCN guidelines. PET/CT is useful in radiation treatment planning and to evaluate for distant metastatic disease. [13] PET/CT can improve inguinal nodal detection with sensitivity and specificity of 93% and 76%, respectively. [14] Sentinel lymph node biopsy may have utility in assessing the inguinal lymph nodes. [15]"}
{"id": "article-31977_11", "title": "Radiation Therapy for Anal Cancer -- Treatment / Management -- Tumors of the Anal Margin", "content": "Anal margin cancers are more commonly diagnosed at an earlier stage and therefore tend to\u00a0have a better prognosis. Management of very early stage anal margin cancer is best by wide local excision or radiotherapy alone, similar to the management of skin cancer. [1] The recommended radiation dose in these cases is between 60 to 65 Gy in 6 to 7 weeks. More advanced disease of the anal margin is treated similarly to anal canal cancers.", "contents": "Radiation Therapy for Anal Cancer -- Treatment / Management -- Tumors of the Anal Margin. Anal margin cancers are more commonly diagnosed at an earlier stage and therefore tend to\u00a0have a better prognosis. Management of very early stage anal margin cancer is best by wide local excision or radiotherapy alone, similar to the management of skin cancer. [1] The recommended radiation dose in these cases is between 60 to 65 Gy in 6 to 7 weeks. More advanced disease of the anal margin is treated similarly to anal canal cancers."}
{"id": "article-31977_12", "title": "Radiation Therapy for Anal Cancer -- Treatment / Management -- Tumors of the Anal Canal", "content": "The traditional management of tumors of the anal canal was via an abdominoperineal resection (APR), resulting in a permanent colostomy. Since the 1980s, there has been a paradigm shift for nonsurgical organ-preserving treatment, and modern management consists of concurrent chemoradiation. While there are no randomized trials comparing APR with chemoradiation, superior colostomy-free survival rates with equivalent survival have established chemoradiation as the preferred modality of treatment. [1] Current radiation techniques involve intensity-modulated radiation therapy (IMRT) to a minimum dose of 45 Gy via conventional fractionation. Concurrent chemotherapy includes a combination of mitomycin C (MMC), 5FU, capecitabine, or cisplatin.", "contents": "Radiation Therapy for Anal Cancer -- Treatment / Management -- Tumors of the Anal Canal. The traditional management of tumors of the anal canal was via an abdominoperineal resection (APR), resulting in a permanent colostomy. Since the 1980s, there has been a paradigm shift for nonsurgical organ-preserving treatment, and modern management consists of concurrent chemoradiation. While there are no randomized trials comparing APR with chemoradiation, superior colostomy-free survival rates with equivalent survival have established chemoradiation as the preferred modality of treatment. [1] Current radiation techniques involve intensity-modulated radiation therapy (IMRT) to a minimum dose of 45 Gy via conventional fractionation. Concurrent chemotherapy includes a combination of mitomycin C (MMC), 5FU, capecitabine, or cisplatin."}
{"id": "article-31977_13", "title": "Radiation Therapy for Anal Cancer -- Treatment / Management -- Suitability for Definitive Treatment", "content": "Performance status must be a consideration when determining a patient\u2019s suitability for definitive treatment. Poor performance status may preclude adherence to conventional chemoradiation. Upfront APR may also be indicated if the patient has bowel incontinence or fistula present at baseline. Other relative reasons that may preclude definitive treatment include prior pelvic radiotherapy or surgery and any underlying medical, psychiatric, and/or social concerns. [1]", "contents": "Radiation Therapy for Anal Cancer -- Treatment / Management -- Suitability for Definitive Treatment. Performance status must be a consideration when determining a patient\u2019s suitability for definitive treatment. Poor performance status may preclude adherence to conventional chemoradiation. Upfront APR may also be indicated if the patient has bowel incontinence or fistula present at baseline. Other relative reasons that may preclude definitive treatment include prior pelvic radiotherapy or surgery and any underlying medical, psychiatric, and/or social concerns. [1]"}
{"id": "article-31977_14", "title": "Radiation Therapy for Anal Cancer -- Treatment / Management -- HIV/AIDS Patients", "content": "People living with HIV have a 15 to 35-fold increase in anal cancer incidence. [9] There is evidence that\u00a0they have higher local relapse rates and higher rates of acute skin toxicity, although there are no observable differences in complete response rates or 5-year OS. [16] HIV-positive patients should continue on antiretroviral therapy throughout chemoradiation. Patients living with HIV should also be evaluated by their CD4 count, making\u00a0appropriate\u00a0chemotherapy adjustments to limit hematologic toxicity. Although concerns for increased hematological toxicity may exist in the HIV-positive patient, standard MMC/ 5FU is the preferred chemotherapeutic regimen with superior outcomes when compared to cisplatin-based chemotherapy. In the setting of poorly controlled HIV with a high viral load, >10000 copies, or very\u00a0low CD4 count with significant concerns for hematologic toxicity, cisplatin-based chemotherapy is acceptable.", "contents": "Radiation Therapy for Anal Cancer -- Treatment / Management -- HIV/AIDS Patients. People living with HIV have a 15 to 35-fold increase in anal cancer incidence. [9] There is evidence that\u00a0they have higher local relapse rates and higher rates of acute skin toxicity, although there are no observable differences in complete response rates or 5-year OS. [16] HIV-positive patients should continue on antiretroviral therapy throughout chemoradiation. Patients living with HIV should also be evaluated by their CD4 count, making\u00a0appropriate\u00a0chemotherapy adjustments to limit hematologic toxicity. Although concerns for increased hematological toxicity may exist in the HIV-positive patient, standard MMC/ 5FU is the preferred chemotherapeutic regimen with superior outcomes when compared to cisplatin-based chemotherapy. In the setting of poorly controlled HIV with a high viral load, >10000 copies, or very\u00a0low CD4 count with significant concerns for hematologic toxicity, cisplatin-based chemotherapy is acceptable."}
{"id": "article-31977_15", "title": "Radiation Therapy for Anal Cancer -- Differential Diagnosis", "content": "The differential diagnosis for anal cancer is broad and dependent upon its clinical presentation. Bright red blood per rectum may also be the result of hemorrhoids, polyps, diverticulosis, anal fissures, ulcers, abscess,\u00a0or proctitis. A sizeable malignant mass at the anus may also originate from the rectum, bladder, prostate, or vagina.", "contents": "Radiation Therapy for Anal Cancer -- Differential Diagnosis. The differential diagnosis for anal cancer is broad and dependent upon its clinical presentation. Bright red blood per rectum may also be the result of hemorrhoids, polyps, diverticulosis, anal fissures, ulcers, abscess,\u00a0or proctitis. A sizeable malignant mass at the anus may also originate from the rectum, bladder, prostate, or vagina."}
{"id": "article-31977_16", "title": "Radiation Therapy for Anal Cancer -- Surgical Oncology", "content": "Historically, APR was the standard of care for anal cancers, resulting in permanent colostomies. General principles for APR are similar to those of distal rectal cancer, which incorporate meticulous total mesorectal excision (TME) and removal of the distal colon, rectum, and anal sphincter complex using both anterior abdominal and perineal incisions. APR alone yields a poor 5-year overall survival rate of 50% and local recurrence rates of 30%. [17] In an effort to reduce the rates of local recurrence, Nigro et al. [18] pioneered a neoadjuvant regimen consisting of chemotherapy and radiation. In his report of 28 patients, 80% experienced a complete pathologic response. These promising results led to multiple randomized clinical trials of anal cancer to validate definitive chemoradiation as primary treatment of anal cancer. Therefore, the role of APR in the modern era is predominantly reserved for salvage treatment or patients with dysfunctional anal sphincters at diagnosis. Adenocarcinomas of the anal canal may also receive treatment with organ preservation. [11]", "contents": "Radiation Therapy for Anal Cancer -- Surgical Oncology. Historically, APR was the standard of care for anal cancers, resulting in permanent colostomies. General principles for APR are similar to those of distal rectal cancer, which incorporate meticulous total mesorectal excision (TME) and removal of the distal colon, rectum, and anal sphincter complex using both anterior abdominal and perineal incisions. APR alone yields a poor 5-year overall survival rate of 50% and local recurrence rates of 30%. [17] In an effort to reduce the rates of local recurrence, Nigro et al. [18] pioneered a neoadjuvant regimen consisting of chemotherapy and radiation. In his report of 28 patients, 80% experienced a complete pathologic response. These promising results led to multiple randomized clinical trials of anal cancer to validate definitive chemoradiation as primary treatment of anal cancer. Therefore, the role of APR in the modern era is predominantly reserved for salvage treatment or patients with dysfunctional anal sphincters at diagnosis. Adenocarcinomas of the anal canal may also receive treatment with organ preservation. [11]"}
{"id": "article-31977_17", "title": "Radiation Therapy for Anal Cancer -- Surgical Oncology", "content": "Local excision with wide margins may be an alternative to chemoradiation in select patients with T1N0M0 anal canal cancers, as long as sphincter function can is preservable. However, the cure rates are markedly lower: 60% at 5 years, with local recurrence rates of 40%. [17] [19] Therefore, local excision alone should be reserved for unique circumstances, such as a patient with poor performance status and/or significant comorbidities. [1]", "contents": "Radiation Therapy for Anal Cancer -- Surgical Oncology. Local excision with wide margins may be an alternative to chemoradiation in select patients with T1N0M0 anal canal cancers, as long as sphincter function can is preservable. However, the cure rates are markedly lower: 60% at 5 years, with local recurrence rates of 40%. [17] [19] Therefore, local excision alone should be reserved for unique circumstances, such as a patient with poor performance status and/or significant comorbidities. [1]"}
{"id": "article-31977_18", "title": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Radiation Alone", "content": "The efficacy of external beam radiation therapy (EBRT) alone in patients with anal cancer has undergone extensive study. In Taboul et al. [20] , local control for primary tumors less than 4 cm was 90% at 10 years, whereas it was 65% for primary tumors greater than 4 cm. Overall, 57% of patients maintained normal anal function. Newmen et al. [21] reported similar results for radiation alone, in which they found that the probability of local control was related to the T stage. Overall, 74% of patients maintained a functional anus. Very few studies have reported on the efficacy of brachytherapy alone. James et al. [22] used interstitial radiotherapy as primary treatment and found a 64% local control for tumors < 5 cm diameter at presentation.", "contents": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Radiation Alone. The efficacy of external beam radiation therapy (EBRT) alone in patients with anal cancer has undergone extensive study. In Taboul et al. [20] , local control for primary tumors less than 4 cm was 90% at 10 years, whereas it was 65% for primary tumors greater than 4 cm. Overall, 57% of patients maintained normal anal function. Newmen et al. [21] reported similar results for radiation alone, in which they found that the probability of local control was related to the T stage. Overall, 74% of patients maintained a functional anus. Very few studies have reported on the efficacy of brachytherapy alone. James et al. [22] used interstitial radiotherapy as primary treatment and found a 64% local control for tumors < 5 cm diameter at presentation."}
{"id": "article-31977_19", "title": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Radiation Alone vs. Chemoradiation", "content": "After the Nigro protocol demonstrated a high rate of complete pathologic response to neoadjuvant chemoradiation, there was the development of multiple randomized clinical trials to validate definitive chemoradiation as primary treatment of anal cancer. Concurrent chemotherapy and radiation yield result superior to those of radiation alone or surgery alone. The two most prominent trials comparing radiation alone to chemoradiation include ACT I and EORTC 22861. The ACT I trial randomized patients to radiation alone vs. chemoradiation with 5FU/MMC. Results indicated\u00a0improved 3-yr local control with chemoradiation vs. radiation alone (64% vs 41%, p < 0.001). [23] A recently published follow-up study on these patients demonstrates a persistent local control benefit after 13 years, with an absolute risk of locoregional recurrence reduced by 25%. [24] Their results were similar to EORTC 22896, with the same randomization, which showed a 5-yr local control improvement from 50 to 68% (p = 0.02) with chemoradiation. Similarly, patients had an improved colostomy-free survival rate with chemoradiation. [25]", "contents": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Radiation Alone vs. Chemoradiation. After the Nigro protocol demonstrated a high rate of complete pathologic response to neoadjuvant chemoradiation, there was the development of multiple randomized clinical trials to validate definitive chemoradiation as primary treatment of anal cancer. Concurrent chemotherapy and radiation yield result superior to those of radiation alone or surgery alone. The two most prominent trials comparing radiation alone to chemoradiation include ACT I and EORTC 22861. The ACT I trial randomized patients to radiation alone vs. chemoradiation with 5FU/MMC. Results indicated\u00a0improved 3-yr local control with chemoradiation vs. radiation alone (64% vs 41%, p < 0.001). [23] A recently published follow-up study on these patients demonstrates a persistent local control benefit after 13 years, with an absolute risk of locoregional recurrence reduced by 25%. [24] Their results were similar to EORTC 22896, with the same randomization, which showed a 5-yr local control improvement from 50 to 68% (p = 0.02) with chemoradiation. Similarly, patients had an improved colostomy-free survival rate with chemoradiation. [25]"}
{"id": "article-31977_20", "title": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Radiation Dose and Technique", "content": "The optimal dose and fractionation of radiation have yet to be fully elucidated. A minimum dose of at least 45 Gy is the current recommendation. One study showed that T1 lesions had effective treatment with a dose of 50 to 60 Gy. [26] Several studies suggest that dose escalation results in higher local control rates. [27] [28] However, the ACCORD 03 trial did not see a benefit in colostomy-free survival or complete response with higher boost doses of radiation up to 70 Gy. [29] Therefore, conventional doses between 50.4 to 59.4 Gy are acceptable, reserving doses at the higher end of the spectrum for bulkier disease.", "contents": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Radiation Dose and Technique. The optimal dose and fractionation of radiation have yet to be fully elucidated. A minimum dose of at least 45 Gy is the current recommendation. One study showed that T1 lesions had effective treatment with a dose of 50 to 60 Gy. [26] Several studies suggest that dose escalation results in higher local control rates. [27] [28] However, the ACCORD 03 trial did not see a benefit in colostomy-free survival or complete response with higher boost doses of radiation up to 70 Gy. [29] Therefore, conventional doses between 50.4 to 59.4 Gy are acceptable, reserving doses at the higher end of the spectrum for bulkier disease."}
{"id": "article-31977_21", "title": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Radiation Dose and Technique", "content": "Techniques associated with radiation therapy have evolved with the utilization of intensity-modulated radiation therapy (IMRT). This inverse planning method of external beam radiotherapy (EBRT) increases the therapeutic ratio by increasing conformal dose to the target structures while reducing the dose to surrounding normal tissue. [30] IMRT\u00a0is clinically associated with decreased acute toxicity when compared to historical outcomes. RTOG 0529 is a phase II study evaluating patients with anal cancer treated with IMRT chemoradiation. T2N0 patients received treatment with a simultaneous integrated boost (SIB) plan prescribing 50.4 Gy to the primary tumor and 42 Gy to elective nodes in 28 fractions. T3-4N0 patients received treatment with a SIB plan delivering\u00a054 Gy to the primary tumor and 45 Gy to elective nodes in 30 fractions. Positive nodes < 3 cm\u00a0were treated to 50.4 Gy in 30 fractions, whereas nodes greater than or equal to 3 cm were treated to 54 Gy in the same 30 fractions. Although the primary endpoint, reducing grade 2+ acute GI/GU toxicity by 15% compared to RTOG 9811,\u00a0was not met, there was significant sparing of grade 2+ hematologic and grade 3+ dermatologic and GI toxicity. [31] It is important to note that quality control and technical aspects of IMRT are challenging, and conformal radiation therapy requires training in target volume contouring, as demonstrated in RTOG 0529 by the number of plans failing\u00a0central review.\u00a0Various contouring atlases are available, including RTOG 0529, Myerson et al., and Ng et al. [31] [32] [33]", "contents": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Radiation Dose and Technique. Techniques associated with radiation therapy have evolved with the utilization of intensity-modulated radiation therapy (IMRT). This inverse planning method of external beam radiotherapy (EBRT) increases the therapeutic ratio by increasing conformal dose to the target structures while reducing the dose to surrounding normal tissue. [30] IMRT\u00a0is clinically associated with decreased acute toxicity when compared to historical outcomes. RTOG 0529 is a phase II study evaluating patients with anal cancer treated with IMRT chemoradiation. T2N0 patients received treatment with a simultaneous integrated boost (SIB) plan prescribing 50.4 Gy to the primary tumor and 42 Gy to elective nodes in 28 fractions. T3-4N0 patients received treatment with a SIB plan delivering\u00a054 Gy to the primary tumor and 45 Gy to elective nodes in 30 fractions. Positive nodes < 3 cm\u00a0were treated to 50.4 Gy in 30 fractions, whereas nodes greater than or equal to 3 cm were treated to 54 Gy in the same 30 fractions. Although the primary endpoint, reducing grade 2+ acute GI/GU toxicity by 15% compared to RTOG 9811,\u00a0was not met, there was significant sparing of grade 2+ hematologic and grade 3+ dermatologic and GI toxicity. [31] It is important to note that quality control and technical aspects of IMRT are challenging, and conformal radiation therapy requires training in target volume contouring, as demonstrated in RTOG 0529 by the number of plans failing\u00a0central review.\u00a0Various contouring atlases are available, including RTOG 0529, Myerson et al., and Ng et al. [31] [32] [33]"}
{"id": "article-31977_22", "title": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Dose Constraints", "content": "The main purpose of dose constraints is to limit the acute and long-term toxicities associated with radiation to the pelvis when using IMRT. RTOG 0529 limited small and large bowel to V45 Gy less than 20 ccs, V35 Gy less than 150 cc, and V30 Gy less than 200 ccs. This resulted in acute grade 2+ GI adverse events of 73% and acute grade 3+ GI adverse events of 21%. The same study limited bladder dose to V50 Gy <= 5%, V40 Gy less than or equal to 35%, and V35 Gy less than or equal to 50%. These constraints limited acute grade 2+ GU adverse events to 15% and acute grade 3+ GU adverse events to 2%. [31] The overall rate of late GI grade 2+ adverse events was 10%, and late GU grade 2+ adverse events were 4%. [34]", "contents": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Dose Constraints. The main purpose of dose constraints is to limit the acute and long-term toxicities associated with radiation to the pelvis when using IMRT. RTOG 0529 limited small and large bowel to V45 Gy less than 20 ccs, V35 Gy less than 150 cc, and V30 Gy less than 200 ccs. This resulted in acute grade 2+ GI adverse events of 73% and acute grade 3+ GI adverse events of 21%. The same study limited bladder dose to V50 Gy <= 5%, V40 Gy less than or equal to 35%, and V35 Gy less than or equal to 50%. These constraints limited acute grade 2+ GU adverse events to 15% and acute grade 3+ GU adverse events to 2%. [31] The overall rate of late GI grade 2+ adverse events was 10%, and late GU grade 2+ adverse events were 4%. [34]"}
{"id": "article-31977_23", "title": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Nodal Metastases", "content": "Lymph node positivity portends a poor prognosis and correlates with worse survival and colostomy rates. [17] Radiation alone controls 70% of involved inguinal nodes, whereas chemoradiation controls 90% of involved inguinal nodes. [35] Therefore, it is important to include mesenteric, iliac, and inguinal lymph nodes within the radiation fields. [31] [32] [33]", "contents": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Nodal Metastases. Lymph node positivity portends a poor prognosis and correlates with worse survival and colostomy rates. [17] Radiation alone controls 70% of involved inguinal nodes, whereas chemoradiation controls 90% of involved inguinal nodes. [35] Therefore, it is important to include mesenteric, iliac, and inguinal lymph nodes within the radiation fields. [31] [32] [33]"}
{"id": "article-31977_24", "title": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Salvage Treatment", "content": "Despite the effectiveness of chemoradiation as definitive management, reports exist of locoregional failure rates of 10 to 30%. [24] [36] Progressive or recurrent disease after definitive chemoradiation requires APR for salvage. Mullen et al. [37] reported an actuarial 5-yr survival rate of 64% in 31 patients after radical salvage surgery. This study also showed that a dose greater than 55 Gy as part of the initial chemoradiation regimen results in a better prognosis after radical salvage surgery.", "contents": "Radiation Therapy for Anal Cancer -- Radiation Oncology -- Salvage Treatment. Despite the effectiveness of chemoradiation as definitive management, reports exist of locoregional failure rates of 10 to 30%. [24] [36] Progressive or recurrent disease after definitive chemoradiation requires APR for salvage. Mullen et al. [37] reported an actuarial 5-yr survival rate of 64% in 31 patients after radical salvage surgery. This study also showed that a dose greater than 55 Gy as part of the initial chemoradiation regimen results in a better prognosis after radical salvage surgery."}
{"id": "article-31977_25", "title": "Radiation Therapy for Anal Cancer -- Medical Oncology -- MMC", "content": "RTOG 87-04 demonstrated a benefit to chemoradiation with MMC and 5FU vs. chemoradiation with 5FU alone. [38] This study showed an improvement in 5-yr LC from 64% to 83% as well as a decreased colostomy rate from 22% to 9% (p = 0.002) with the addition of MMC.", "contents": "Radiation Therapy for Anal Cancer -- Medical Oncology -- MMC. RTOG 87-04 demonstrated a benefit to chemoradiation with MMC and 5FU vs. chemoradiation with 5FU alone. [38] This study showed an improvement in 5-yr LC from 64% to 83% as well as a decreased colostomy rate from 22% to 9% (p = 0.002) with the addition of MMC."}
{"id": "article-31977_26", "title": "Radiation Therapy for Anal Cancer -- Medical Oncology -- Capecitabine", "content": "Capecitabine is an acceptable alternative to 5FU in the treatment of colon and rectal cancer with fewer hematologic toxicities, and it has therefore merited consideration as an alternative to 5FU in chemoradiation regimens for anal cancer. Although data for this regimen are limited, multiple retrospective studies have shown adequate LC, OS, and colostomy-free survival in this group of patients. [39] [40]", "contents": "Radiation Therapy for Anal Cancer -- Medical Oncology -- Capecitabine. Capecitabine is an acceptable alternative to 5FU in the treatment of colon and rectal cancer with fewer hematologic toxicities, and it has therefore merited consideration as an alternative to 5FU in chemoradiation regimens for anal cancer. Although data for this regimen are limited, multiple retrospective studies have shown adequate LC, OS, and colostomy-free survival in this group of patients. [39] [40]"}
{"id": "article-31977_27", "title": "Radiation Therapy for Anal Cancer -- Medical Oncology -- Cisplatin", "content": "Cisplatin as a substitute for MMC has undergone evaluation in multiple phase II studies showing promising results for chemoradiation with 5FU and cisplatin. [41] [42] Fewer hematologic and other toxicities are evident with cisplatin relative to MMC. The ACT II trial compared cisplatin with MMC and looked at the effect of additional maintenance chemotherapy following definitive chemoradiation. In this study, patients were randomly assigned to 5FU/MMC or 5FU/cisplatin with 50.4 Gy concurrent radiation. Each patient then underwent a second randomization receiving two cycles of maintenance therapy with 5FU and cisplatin vs. no maintenance therapy. There was no difference among any arm of the study, and because it was not a non-inferiority trial, they concluded that 5FU and MMC should remain the\u00a0standard of care. [43] Also, this trial confirmed that assessment for treatment response should not commence prior to 26 weeks unless there is a clear progression of the disease. [44] RTOG 9811 was a two-arm trial evaluating\u00a0the utilization of cisplatin as a replacement for MMC.\u00a0Induction cisplatin plus concurrent chemoradiation with cisplatin/5FU was compared to the standard of concurrent chemoradiation with 5FU/MMC. Results were inferior in the cisplatin/5FU arm as compared to standard chemoradiation with 5FU/MMC. [45] The use of induction cisplatin in this study may have confounded the results because of the delay in the completion of therapy. The cisplatin arm resulted in worse 5-yr OS (70.7% vs. 78.3%, p = 0.026), DFS (57.8% vs. 67.8%, p = 0.006), and colostomy-free survival (65% vs. 71.9%, p = 0.05) compared to the MMC arm. [46] Chemoradiation with trimodal therapy, including 5FU, MMC, and cisplatin, was studied in a phase II trial but found to be too toxic. [27] Taken together, these studies support 5FU and MMC remaining the standard of care in concurrent chemoradiation with the possibility of using 5FU/cisplatin in the rare patient at high risk for excessive hematologic toxicity\u00a0from MMC.", "contents": "Radiation Therapy for Anal Cancer -- Medical Oncology -- Cisplatin. Cisplatin as a substitute for MMC has undergone evaluation in multiple phase II studies showing promising results for chemoradiation with 5FU and cisplatin. [41] [42] Fewer hematologic and other toxicities are evident with cisplatin relative to MMC. The ACT II trial compared cisplatin with MMC and looked at the effect of additional maintenance chemotherapy following definitive chemoradiation. In this study, patients were randomly assigned to 5FU/MMC or 5FU/cisplatin with 50.4 Gy concurrent radiation. Each patient then underwent a second randomization receiving two cycles of maintenance therapy with 5FU and cisplatin vs. no maintenance therapy. There was no difference among any arm of the study, and because it was not a non-inferiority trial, they concluded that 5FU and MMC should remain the\u00a0standard of care. [43] Also, this trial confirmed that assessment for treatment response should not commence prior to 26 weeks unless there is a clear progression of the disease. [44] RTOG 9811 was a two-arm trial evaluating\u00a0the utilization of cisplatin as a replacement for MMC.\u00a0Induction cisplatin plus concurrent chemoradiation with cisplatin/5FU was compared to the standard of concurrent chemoradiation with 5FU/MMC. Results were inferior in the cisplatin/5FU arm as compared to standard chemoradiation with 5FU/MMC. [45] The use of induction cisplatin in this study may have confounded the results because of the delay in the completion of therapy. The cisplatin arm resulted in worse 5-yr OS (70.7% vs. 78.3%, p = 0.026), DFS (57.8% vs. 67.8%, p = 0.006), and colostomy-free survival (65% vs. 71.9%, p = 0.05) compared to the MMC arm. [46] Chemoradiation with trimodal therapy, including 5FU, MMC, and cisplatin, was studied in a phase II trial but found to be too toxic. [27] Taken together, these studies support 5FU and MMC remaining the standard of care in concurrent chemoradiation with the possibility of using 5FU/cisplatin in the rare patient at high risk for excessive hematologic toxicity\u00a0from MMC."}
{"id": "article-31977_28", "title": "Radiation Therapy for Anal Cancer -- Medical Oncology -- Induction", "content": "According to ACCORD 03, induction chemotherapy with 5FU and cisplatin offers no benefit in survival, complete response, or colostomy-free survival. [29] This trial had two randomizations, one that looked at higher boost doses of radiation (as discussed previously), and the other evaluated two cycles of induction chemotherapy with 5FU/cisplatin vs. no induction chemotherapy. Additionally, RTOG 9811, as discussed\u00a0above, demonstrated\u00a0a detriment in OS, DFS, and colostomy-free survival with induction cisplatin. [45]", "contents": "Radiation Therapy for Anal Cancer -- Medical Oncology -- Induction. According to ACCORD 03, induction chemotherapy with 5FU and cisplatin offers no benefit in survival, complete response, or colostomy-free survival. [29] This trial had two randomizations, one that looked at higher boost doses of radiation (as discussed previously), and the other evaluated two cycles of induction chemotherapy with 5FU/cisplatin vs. no induction chemotherapy. Additionally, RTOG 9811, as discussed\u00a0above, demonstrated\u00a0a detriment in OS, DFS, and colostomy-free survival with induction cisplatin. [45]"}
{"id": "article-31977_29", "title": "Radiation Therapy for Anal Cancer -- Medical Oncology -- Metastatic", "content": "First-line treatment of metastatic anal cancer includes a fluoropyrimidine-based regimen plus cisplatin. Additional regimens may include carboplatin plus paclitaxel or mFOLFOX. Second-line systemic therapies may include the anti-PD-1 antibody nivolumab, which has a 17% response rate in the KEYNOTE-028 study. [36] Palliative radiation should\u00a0be a consideration for symptomatic metastases, and chemoradiation may be an option for local control of bulky primary disease.", "contents": "Radiation Therapy for Anal Cancer -- Medical Oncology -- Metastatic. First-line treatment of metastatic anal cancer includes a fluoropyrimidine-based regimen plus cisplatin. Additional regimens may include carboplatin plus paclitaxel or mFOLFOX. Second-line systemic therapies may include the anti-PD-1 antibody nivolumab, which has a 17% response rate in the KEYNOTE-028 study. [36] Palliative radiation should\u00a0be a consideration for symptomatic metastases, and chemoradiation may be an option for local control of bulky primary disease."}
{"id": "article-31977_30", "title": "Radiation Therapy for Anal Cancer -- Staging", "content": "Several clinical staging systems have been used in the past. The TNM (tumor, nodes, metastases) classification system developed by the American Joint Committee on Cancer (AJCC) is the most widely accepted classification system. TNM staging may use a combination of physical examination, positron emission tomography (PET), magnetic resonance imaging (MRI), and/or computed tomography (CT) to identify the primary tumor, involved nodes, and metastatic disease if present. [1] If there is discordant or indeterminate imaging, pathologic staging with a sentinel lymph node biopsy may be an option. [47] Unlike other GI malignancies, anal cancer\u00a0T-stage is based primarily on tumor size rather than depth of invasion. A\u00a0major change in the revision from AJCC 7th to 8th edition staging is with nodal staging. Previously lymph node staging was denoted as N1, N2, or N3 based on the location of regional nodes, which has undergone revision to a more straightforward N0-N1 designation based on the presence of lymph nodes.\u00a0The N1\u00a0category now\u00a0subdivides into N1a, N1b, and N1c based on the location of the nodes. This change is\u00a0due to long-term outcomes of RTOG 98-11, demonstrating\u00a0overall survival is impacted primarily by nodal positivity\u00a0rather than the location of regional nodes. [48]", "contents": "Radiation Therapy for Anal Cancer -- Staging. Several clinical staging systems have been used in the past. The TNM (tumor, nodes, metastases) classification system developed by the American Joint Committee on Cancer (AJCC) is the most widely accepted classification system. TNM staging may use a combination of physical examination, positron emission tomography (PET), magnetic resonance imaging (MRI), and/or computed tomography (CT) to identify the primary tumor, involved nodes, and metastatic disease if present. [1] If there is discordant or indeterminate imaging, pathologic staging with a sentinel lymph node biopsy may be an option. [47] Unlike other GI malignancies, anal cancer\u00a0T-stage is based primarily on tumor size rather than depth of invasion. A\u00a0major change in the revision from AJCC 7th to 8th edition staging is with nodal staging. Previously lymph node staging was denoted as N1, N2, or N3 based on the location of regional nodes, which has undergone revision to a more straightforward N0-N1 designation based on the presence of lymph nodes.\u00a0The N1\u00a0category now\u00a0subdivides into N1a, N1b, and N1c based on the location of the nodes. This change is\u00a0due to long-term outcomes of RTOG 98-11, demonstrating\u00a0overall survival is impacted primarily by nodal positivity\u00a0rather than the location of regional nodes. [48]"}
{"id": "article-31977_31", "title": "Radiation Therapy for Anal Cancer -- Staging -- Primary Tumor (T)", "content": "TX: Primary tumor not assessed T0: No evidence of primary tumor Tis: High-grade squamous intraepithelial lesion T1: Tumor 2 cm or less T2: Tumor more than 2 cm but not more than 5 cm T3: Tumor more than 5 cm T4: Tumor of any size that invades adjacent organ(s), including vagina, urethra, or bladder", "contents": "Radiation Therapy for Anal Cancer -- Staging -- Primary Tumor (T). TX: Primary tumor not assessed T0: No evidence of primary tumor Tis: High-grade squamous intraepithelial lesion T1: Tumor 2 cm or less T2: Tumor more than 2 cm but not more than 5 cm T3: Tumor more than 5 cm T4: Tumor of any size that invades adjacent organ(s), including vagina, urethra, or bladder"}
{"id": "article-31977_32", "title": "Radiation Therapy for Anal Cancer -- Staging -- Regional Lymph Nodes (N)", "content": "NX: Regional lymph nodes cannot be assessed N0: No regional lymph node metastasis N1: Regional lymph node metastasis present N1a: Metastasis in inguinal, mesorectal, or internal iliac lymph nodes N1b: Metastasis in external iliac lymph nodes N1c: Metastasis in external iliac with any N1a nodes", "contents": "Radiation Therapy for Anal Cancer -- Staging -- Regional Lymph Nodes (N). NX: Regional lymph nodes cannot be assessed N0: No regional lymph node metastasis N1: Regional lymph node metastasis present N1a: Metastasis in inguinal, mesorectal, or internal iliac lymph nodes N1b: Metastasis in external iliac lymph nodes N1c: Metastasis in external iliac with any N1a nodes"}
{"id": "article-31977_33", "title": "Radiation Therapy for Anal Cancer -- Staging -- Distant Metastasis (M)", "content": "M0: No distant metastasis M1: Distant Metastasis", "contents": "Radiation Therapy for Anal Cancer -- Staging -- Distant Metastasis (M). M0: No distant metastasis M1: Distant Metastasis"}
{"id": "article-31977_34", "title": "Radiation Therapy for Anal Cancer -- Staging -- Anatomic Stage/Prognostic Groups:", "content": "Stage 0:\u00a0 \u00a0 \u00a0 \u00a0Tis\u00a0 \u00a0 \u00a0 N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage I:\u00a0 \u00a0 \u00a0 \u00a0 T1\u00a0 \u00a0 \u00a0 N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIA:\u00a0 \u00a0 \u00a0T2\u00a0 \u00a0 \u00a0 N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIB:\u00a0 \u00a0 \u00a0T3\u00a0 \u00a0 \u00a0 N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIIA:\u00a0 \u00a0T1-2\u00a0 \u00a0 N1\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIIB:\u00a0 \u00a0T4\u00a0 \u00a0 \u00a0 \u00a0N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIIC:\u00a0 \u00a0T3-4\u00a0 \u00a0 N1\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IV:\u00a0 \u00a0 \u00a0Any T\u00a0 Any N\u00a0 \u00a0M1", "contents": "Radiation Therapy for Anal Cancer -- Staging -- Anatomic Stage/Prognostic Groups:. Stage 0:\u00a0 \u00a0 \u00a0 \u00a0Tis\u00a0 \u00a0 \u00a0 N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage I:\u00a0 \u00a0 \u00a0 \u00a0 T1\u00a0 \u00a0 \u00a0 N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIA:\u00a0 \u00a0 \u00a0T2\u00a0 \u00a0 \u00a0 N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIB:\u00a0 \u00a0 \u00a0T3\u00a0 \u00a0 \u00a0 N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIIA:\u00a0 \u00a0T1-2\u00a0 \u00a0 N1\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIIB:\u00a0 \u00a0T4\u00a0 \u00a0 \u00a0 \u00a0N0\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IIIC:\u00a0 \u00a0T3-4\u00a0 \u00a0 N1\u00a0 \u00a0 \u00a0 \u00a0 M0 Stage IV:\u00a0 \u00a0 \u00a0Any T\u00a0 Any N\u00a0 \u00a0M1"}
{"id": "article-31977_35", "title": "Radiation Therapy for Anal Cancer -- Prognosis", "content": "A large primary tumor, the presence of nodal or distant metastases, male sex, and HIV positivity are poor prognostic factors. [49] Patients with de novo tumors > 5 cm are at increased risk of requiring a colostomy [50] . Fifty to sixty percent of patients present with lesions < 5 cm, with an associated 5-year overall survival (OS) rate of 80 to 90%. The incidence of nodal metastases can range from 10 to 60% depending upon the T stage, which lowers the survival rate to 60% at 5 years. The observed 5-year OS rate based on AJCC 7 edition stage for squamous cell carcinoma of the anus was: 77% for stage I, 67% for stage II, 58% for stage IIIA, 51% for stage IIIB, and 15% for stage IV.", "contents": "Radiation Therapy for Anal Cancer -- Prognosis. A large primary tumor, the presence of nodal or distant metastases, male sex, and HIV positivity are poor prognostic factors. [49] Patients with de novo tumors > 5 cm are at increased risk of requiring a colostomy [50] . Fifty to sixty percent of patients present with lesions < 5 cm, with an associated 5-year overall survival (OS) rate of 80 to 90%. The incidence of nodal metastases can range from 10 to 60% depending upon the T stage, which lowers the survival rate to 60% at 5 years. The observed 5-year OS rate based on AJCC 7 edition stage for squamous cell carcinoma of the anus was: 77% for stage I, 67% for stage II, 58% for stage IIIA, 51% for stage IIIB, and 15% for stage IV."}
{"id": "article-31977_36", "title": "Radiation Therapy for Anal Cancer -- Prognosis", "content": "Surveillance following definitive treatment involves a DRE between 8 and 12 weeks after completion of chemoradiation. Patients then get classified according to whether they have a complete response, partial response, or progressive disease. If they have persistent disease at that time\u00a0without progression, patients should be managed with close follow up to determine if further regression occurs. Persistent disease may continue to regress even at 26 weeks from the start of treatment, thus avoiding APR in these patients [43] . If they have biopsy-proven disease after 26 weeks, or if they have progressive disease at any point, then further intensive treatment is warranted. While there is insufficient evidence to recommend routine use of PET/CT in the assessment of treatment response, a complete response on PET/CT is a good prognostic factor for overall survival and progression-free survival [14] .", "contents": "Radiation Therapy for Anal Cancer -- Prognosis. Surveillance following definitive treatment involves a DRE between 8 and 12 weeks after completion of chemoradiation. Patients then get classified according to whether they have a complete response, partial response, or progressive disease. If they have persistent disease at that time\u00a0without progression, patients should be managed with close follow up to determine if further regression occurs. Persistent disease may continue to regress even at 26 weeks from the start of treatment, thus avoiding APR in these patients [43] . If they have biopsy-proven disease after 26 weeks, or if they have progressive disease at any point, then further intensive treatment is warranted. While there is insufficient evidence to recommend routine use of PET/CT in the assessment of treatment response, a complete response on PET/CT is a good prognostic factor for overall survival and progression-free survival [14] ."}
{"id": "article-31977_37", "title": "Radiation Therapy for Anal Cancer -- Complications", "content": "Patients treated with IMRT have improved long-term toxicities relative to patients treated with conventional radiation techniques. The cumulative acute non-hematologic grade 3+ toxicity rate is ~20%. The most common non-hematologic acute toxicities include desquamation, proctitis, cystitis, and diarrhea. The cumulative rate of acute hematologic grade 3+ toxicity is ~60%, most commonly neutropenia. The most common late toxicity is grade 1 diarrhea in ~35%, which is manageable with conservative interventions. Additional long-term toxicities of chemoradiation include persistent radiation proctitis, angioectasias, and, less commonly, hip fractures, fistulas, sexual dysfunction, or strictures. [34]", "contents": "Radiation Therapy for Anal Cancer -- Complications. Patients treated with IMRT have improved long-term toxicities relative to patients treated with conventional radiation techniques. The cumulative acute non-hematologic grade 3+ toxicity rate is ~20%. The most common non-hematologic acute toxicities include desquamation, proctitis, cystitis, and diarrhea. The cumulative rate of acute hematologic grade 3+ toxicity is ~60%, most commonly neutropenia. The most common late toxicity is grade 1 diarrhea in ~35%, which is manageable with conservative interventions. Additional long-term toxicities of chemoradiation include persistent radiation proctitis, angioectasias, and, less commonly, hip fractures, fistulas, sexual dysfunction, or strictures. [34]"}
{"id": "article-31977_38", "title": "Radiation Therapy for Anal Cancer -- Deterrence and Patient Education", "content": "Patients at high risk for this disease should receive education about symptoms and risk factors for anal cancer, including patients with HIV, multiple sexual partners, chronic immunosuppression not due to HIV, and chronic inflammatory states such as Crohn disease. HPV vaccines, when given before HPV exposure, may reduce the risk of anal cancer and need to be more widely utilized, especially in\u00a0high-risk populations. [8]", "contents": "Radiation Therapy for Anal Cancer -- Deterrence and Patient Education. Patients at high risk for this disease should receive education about symptoms and risk factors for anal cancer, including patients with HIV, multiple sexual partners, chronic immunosuppression not due to HIV, and chronic inflammatory states such as Crohn disease. HPV vaccines, when given before HPV exposure, may reduce the risk of anal cancer and need to be more widely utilized, especially in\u00a0high-risk populations. [8]"}
{"id": "article-31977_39", "title": "Radiation Therapy for Anal Cancer -- Pearls and Other Issues", "content": "Chemoradiation with 5FU and MMC remains the standard of care Radiation doses of 50.4-54 Gy and up to 59.4 Gy for bulky disease are the most common doses with IMRT APR is generally\u00a0reserved for salvage", "contents": "Radiation Therapy for Anal Cancer -- Pearls and Other Issues. Chemoradiation with 5FU and MMC remains the standard of care Radiation doses of 50.4-54 Gy and up to 59.4 Gy for bulky disease are the most common doses with IMRT APR is generally\u00a0reserved for salvage"}
{"id": "article-31977_40", "title": "Radiation Therapy for Anal Cancer -- Enhancing Healthcare Team Outcomes", "content": "The management of anal cancer requires an interprofessional discussion involving the physician subspecialties of radiology, pathology, radiation oncology, medical oncology, and surgical oncology to ensure proper diagnosis and staging as well as determine\u00a0the optimal course of treatment. Also, the role of nurses, pharmacists, radiation therapists, physicists, and dosimetrists is crucial. Nurses help monitor patients during and after their treatment for pain, infection, and a variety of treatment-related complications. Pharmacists, including board-certified oncology pharmacists, dispense the recommended medications and chemotherapeutic agents in coordination with the oncology staff. Dosimetrists and physicists help the radiation oncologist develop a treatment plan\u00a0delivered by the radiation therapist. Cancers of the lower GI tract require ample communication between all levels of health professionals working as an interprofessional team to improve outcomes and enhance patient safety. [51]", "contents": "Radiation Therapy for Anal Cancer -- Enhancing Healthcare Team Outcomes. The management of anal cancer requires an interprofessional discussion involving the physician subspecialties of radiology, pathology, radiation oncology, medical oncology, and surgical oncology to ensure proper diagnosis and staging as well as determine\u00a0the optimal course of treatment. Also, the role of nurses, pharmacists, radiation therapists, physicists, and dosimetrists is crucial. Nurses help monitor patients during and after their treatment for pain, infection, and a variety of treatment-related complications. Pharmacists, including board-certified oncology pharmacists, dispense the recommended medications and chemotherapeutic agents in coordination with the oncology staff. Dosimetrists and physicists help the radiation oncologist develop a treatment plan\u00a0delivered by the radiation therapist. Cancers of the lower GI tract require ample communication between all levels of health professionals working as an interprofessional team to improve outcomes and enhance patient safety. [51]"}
{"id": "article-31977_41", "title": "Radiation Therapy for Anal Cancer -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Radiation Therapy for Anal Cancer -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}